Consolidative thoracic radiotherapy for extensive stage small cell lung cancer

Xiaoli Zhang, Jinming Yu _, Hui Zhu, Xue Meng, Minghuan Li, Liyang Jiang, Xingchen Ding and Xindong Sun

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:22251-22261. https://doi.org/10.18632/oncotarget.14759

Metrics: PDF 4080 views  |   HTML 3545 views  |   ?  


Xiaoli Zhang1,2, Jinming Yu1,2,3, Hui Zhu2,3, Xue Meng2,3, Minghuan Li2,3, Liyang Jiang2,3, Xingchen Ding2,4 and Xindong Sun2,3

1. Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China

2. Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, Jinan, China

3. Shandong Academy of Medical Sciences, Jinan University, Jinan, China

4. Weifang Medical University, Weifang, China

Correspondence to:

Jinming Yu, email:

Keywords: small cell lung cancer, extensive stage, thoracic radiotherapy

Received: November 09, 2016 Accepted: January 11, 2017 Published: January 19, 2017


Extensive stage small cell lung cancer (ES-SCLC) represents approximately half of all diagnosed small cell lung cancer worldwide. It is notorious for a high risk of local recurrence although it’s sensitive to chemotherapy. Nearly 90% of intrathoracic failures happen in the first year after diagnosis. The cornerstone of treatment for ES-SCLC is etoposide-platinum based chemotherapy. Consolidative radiotherapy to thorax has diminished the incidence of local relapse, therefore it should be offered to patients with excellent response to induction first-line chemotherapy. This review centers on the clinical evidence for the use of thoracic radiotherapy (TRT) and current modalities of TRT delivery, then tries to determine a feasible way to conduct TRT in a selective group of cases.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14759